Your AI-Trained Oncology Knowledge Connection!
Often excluded from early trials, adults with high-grade gliomas may be good candidates for solid tumor phase I studies of single agents, according to a new analysis.
A new study identified the molecule known as N1,N12-diacetylspermine as a potential biomarker for early-stage non–small-cell lung cancer.
Both chemotherapy and anti-HER2 therapy can improve survival in HER2-positive breast cancer patients with brain metastases who undergo whole-brain radiotherapy.
Differences in failure-to-rescue rates may explain a wide variation in mortality in patients undergoing lung cancer resection at different hospitals, according to a new study.
Use of the diabetes drug pioglitazone was not associated with a significantly increased risk of bladder cancer, in a large cohort study.
Ponatinib yielded complete cytogenetic responses in most patients with newly diagnosed chronic-phase CML, but the risk of vascular events suggests other agents should first be considered.
New classification guidelines for histologic subtypes of stage I lung adenocarcinoma offer prognostic value, according to a recent study.
Limited resection is not as effective as lobectomy in older patients with early-stage lung cancer, according to a new study.
Treatment of CML with various tyrosine kinase inhibitors can induce changes in glomerular filtration rate over time and have other kidney-related effects.
Results of a study suggest that durable survival is possible in melanoma patients treated with MAPK inhibitors, and is perhaps similar to the survival observed with ipilimumab.
A retrospective study was used to develop nomograms predictive of both metastasis-free and overall survival for patients with nonmetastatic osteosarcoma.
Whole-exome sequencing found that mutations of the NF1 gene are an important driver mutation in melanoma, and the third most frequently mutated gene.
Six carbonyl compounds in exhaled breath can effectively discriminate between lung cancer patients and healthy patients, says a new study.
The FDA approved the proteasome inhibitor carfilzomib for the treatment of multiple myeloma, when used in combination with lenalidomide and dexamethasone.
In a phase I study, gemcitabine given concurrently with fixed-dose EBRT showed promising results following surgery in patients with high-risk soft-tissue sarcoma.
Patients diagnosed with colorectal cancer at younger ages are more likely to have an underlying hereditary syndrome than older patients, according to a new study.
The use of BEAMing technology on circulating DNA to identify multiple mutations in real time could help guide treatment in colorectal cancer patients.
Adding tivantinib to erlotinib improved progression-free survival but not overall survival in patients with previously treated non-small-cell lung cancer.
The FDA has granted Orphan Drug Designation to the immunotherapy DPX-Survivac, which is in development for the treatment of ovarian cancer.
Long-term follow-up of a phase II study shows that nilotinib is highly effective in treating chronic phase CML as a first-line therapy, though with relatively common cardiovascular toxicity associated with treatment.
The use of CT-guided radiofrequency ablation is well tolerated and effective among patients with inoperable stage IA non-small-cell lung cancer.
Patients with CML undergoing treatment with dasatinib had a narrower spectrum of mutations in BCR-ABL1 compared to those treated with imatinib.
A new meta-analysis suggests that de-escalation of bone-targeted agents is a safe strategy in breast cancer patients with bone metastases.
Use of post-operative radiotherapy was associated with better overall survival in patients with incompletely resected stage II/III non-small-cell lung cancer.
Large proportions of lung and colorectal cancer patients believe that surgery will cure their cancer, according to results of a new population-based study.
The combination of pemetrexed/cisplatin was superior to gemcitabine/cisplatin in non-squamous NSCLC patients negative for the thymidylate synthase enzyme.
The presence of cervical lymph node metastases was associated with compromised survival even in younger patients with papillary thyroid cancer.
Neoadjuvant TDM-1 was shown to be effective in treating HER2-positive, HR-positive breast cancer compared with trastuzumab, with or without endocrine therapy.
Alectinib yielded good response rates and was very well tolerated in a phase II trial of patients with advanced, ALK-positive non–small-cell lung cancer.
The addition of pertuzumab to trastuzumab and docetaxel offers significant improvement over other options in patients with HER2-positive breast cancer.